AC
IOVA icon

Apogem Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Apogem Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,800
Closed -$192K – 190
2021
Q3 		$192K Buy
+7,800
New +$184K 0.12% 175

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Apogem Capital's IOVA Position: Q4 2021 in Review

Apogem Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 21,132 shares — an estimated $521K sold.

Apogem Capital first reported a position in IOVA in Q2 2021 and held it in 2 quarters. The position peaked at $521K in Q3 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Apogem Capital reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Apogem Capital sold 21,132 Iovance Biotherapeutics shares in Q4 2021, an estimated $521K.
  • Apogem Capital first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Apogem Capital's Iovance Biotherapeutics position peaked at $521K in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.